Calidi Biotherapeutics Announces the Appointment of Three New Members to its Scientific and Medical Advisory Board
Retrieved on:
Monday, January 8, 2024
Oncology, Health, Stem Cells, Neurology, Research, Science, Biotechnology, Virus, Cell, Cancer, Distinguishing, University, Biologic, Dove Medical Press, Neuroscience, UAB Hospital, Emory University, National academy, UAB, Glioblastoma, Radiation therapy, Neuro, Nature Biotechnology, Physician, Birmingham School of Law, Engineering, Neurosurgery, Potyvirus, Harvard Medical School, Supernova, Pulmonology, Hospital, Bangladesh Technical Education Board, University of Groningen, PNAS, Pharmaceutical industry
Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies today announced the appointment of three new members to its Scientific and Medical Advisory Board.
Key Points:
- Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies today announced the appointment of three new members to its Scientific and Medical Advisory Board.
- “Calidi continues to expand our Scientific and Medical Advisory Board, adding leading physicians and scientists from the top cancer hospitals and research institutions in the United States,” said Allan Camaisa, CEO and Chairman of the Board of Calidi Biotherapeutics.
- Dr. Chiocca is a faculty member at Harvard Medical School and leads a laboratory focused on developing novel genetic therapies for malignant brain tumors.
- from the University of Tennessee and completed his residency and fellowship at UAB Hospital in Neurology and Neuro-oncology.